ArticleJournal of bacteriology1999
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.
Article in Journal of bacteriology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.
- A bibliometric and visual analysis of research on echinocandin treatment for urinary tract infections based on VOSviewer and CiteSpace.Frontiers in cellular and infection microbiology · 2026Pooled it
- Article
- Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi.Cell · 2026Article
- Mitochondrial cardiolipin sequestration of caspofungin underliesbioRxiv : the preprint server for biology · 2026Article
- Advances in cryptococcal infections-associated immunopathology and potential therapeutic strategies.Frontiers in pharmacology · 2026Review
- The protein phosphatase 2C domain contributes to the pathobiological function of adenylyl cyclase inbioRxiv : the preprint server for biology · 2025Article
- Genomic Characterization ofVeterinary sciences · 2025Article
- Butyrolactol A potentiates caspofungin efficacy against resistant fungi via phospholipid flippase inhibition.bioRxiv : the preprint server for biology · 2025Article
- An auxin-inducible degron system for conditional mutation in the fungal meningitis pathogen Cryptococcus neoformans.G3 (Bethesda, Md.) · 2025Article
- Adaptation of the tetracycline-repressible system for modulating the expression of essential genes inmSphere · 2025Article
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- Fungal β-1,3-glucan synthase: a review of structure, mechanism, and regulation.FEMS yeast research · 2025Review
- Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.Journal of fungi (Basel, Switzerland) · 2024Review
- A fungal protein organizes both glycogen and cell wall glucans.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Pleurotus ostreatus as a model mushroom in genetics, cell biology, and material sciences.Applied microbiology and biotechnology · 2024Review
- Pleiotropic roles of LAMMER kinase, Lkh1 in stress responses and virulence ofFrontiers in cellular and infection microbiology · 2024Article
- Aneuploidy underlies brefeldin A-induced antifungal drug resistance inFrontiers in cellular and infection microbiology · 2024Article
- Rise and fall of Caspofungin: the current status of Caspofungin as a treatment forFuture microbiology · 2024Review
- Article
- Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcal meningitis is a fungal infection, caused by Cryptococcus neoformans, which is prevalent in immunocompromised patient populations. Treatment failures of this disease are emerging in the clinic, usually associated with long-term treatment with existing antifungal agents. The fungal cell wall is an attractive target for drug therapy because the syntheses of cell wall glucan and chitin are processes that are absent in mammalian cells. Echinocandins comprise a class of lipopeptide compounds known to inhibit 1,3-beta-glucan synthesis, and at least two compounds belonging to this class are currently in clinical trials as therapy for life-threatening fungal infections. Studies of Saccharomyces cerevisiae and Candida albicans mutants identify the membrane-spanning subunit of glucan synthase, encoded by the FKS genes, as the molecular target of echinocandins. In vitro, the echinocandins show potent antifungal activity against Candida and Aspergillus species but are much less potent against C. neoformans. In order to examine why C. neoformans cells are less susceptible to echinocandin treatment, we have cloned a homolog of S. cerevisiae FKS1 from C. neoformans. We have developed a generalized method to evaluate the essentiality of genes in Cryptococcus and applied it to the FKS1 gene. The method relies on homologous integrative transformation with a plasmid that can integrate in two orientations, only one of which will disrupt the target gene function. The results of this analysis suggest that the C. neoformans FKS1 gene is essential for viability. The C. neoformans FKS1 sequence is closely related to the FKS1 sequences from other fungal species and appears to be single copy in C. neoformans. Furthermore, amino acid residues known to be critical for echinocandin susceptibility in Saccharomyces are conserved in the C. neoformans FKS1 sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.